Tagged with BIO

Mexico José Luis Hernández, general manager at Kedrion Mexico, explains the strategy followed by the affiliate in Mexico to obtain success during the past eight years and showcases the added value of plasma-derivate solutions both for patients and government. What are the primary activities and operations of Kedrion in Mexico? Kedrion…

Switzerland With a population of only 350,000, Ticino has a remarkably well developed pharmaceutical cluster. FIT Chairman Giorgio Calderari explains that the cluster’s key strength lies in the diverse range of capabilities which its members are able to offer as contract services to one another, and of course other interested third…

Mexico Maarten Pouw, business unit director of Mexico and Latin America at DSM Sinochem Pharmaceuticals, explains the crucial role that sustainable antibiotics play in combating antimicrobial resistance and showcases the company’s region-wide commitment to offering reliable, compliant and sustainable APIs. Could you please introduce to our international audience the key activities…

Taiwan Yita Lee & Muh-Hwan Su of Sinphar Group & SynCore Bio describe the exciting R&D projects of SynCore Bio, the oncology & dry AMD focused innovation-driven company of the group, and the advantages of SynCore Bio’s integration within Sinphar Group. As an introduction to our international readers, could you provide…

Ireland Much like the Irish sport of hurling, conducting R&D in Ireland is something often overlooked – unfairly, as proponents would say. Ireland has always faced a number of intrinsic hurdles in this space, not least the small patient population and more recently, the economic crisis, which forced the Irish healthcare…

Taiwan Jonas Wang Ph.D., Chairman and CEO of StemCyte, a global leader in Regenerative Therapy field including cell processing and transplantation located in the US, Taiwan, and India, provides us with an overview of the impressive phase II results recently received by its breakthrough regenerative therapy for spinal cord injury. While…

Taiwan In an exclusive interview conducted on the 22nd of December 2016, Taiwan’s Minister of Health and Welfare Lin Tzou-yien discussed improving Taiwan’s National Health Insurance (NHI), ensuring that Taiwanese patients can access innovative treatments, and nurturing the development of Taiwan’s thriving R&D-driven pharmaceutical and biotech industries. Minister Lin, you became…

Mexico Juan Francisco Hernández, general manager of Latin America at Wockhardt, showcases the added value of the company to the entire region based on quality, safety and cost-effective medicines targeting diabetes, CNS and anti-infective areas. Could you introduce yourself to our international readers as well as the key activities and operations…

Mexico María Teresa Lopez, managing director at Zimmer Biomet Mexico, discusses the medtech company’s strong commitment to Mexico as well as the high added value of its broad and innovative health solutions to enhance patients’ quality of life. Please introduce the main activities of Zimmer Biomet in Mexico and the Mexican…

Switzerland www.celonic.com CEO of Swiss biologics CDMO Celonic, Konstantin Matentzoglu, explains how the company attracts talented and experienced staff and what makes it the partner of choice in Switzerland and beyond. Celonic is in many ways more than a CDMO for biologics. What is the strategic focus of this company? “Our…

Switzerland Jesús Martin-Garcia, Chairman and CEO of GeNeuro, discusses their positive partnership with Servier to develop an antibody against a possible cause of MS, as well as the reasons for choosing Geneva when working with multiple sclerosis. Following 15 years of research performed by French-based Institut Mérieux and INSERM, GeNeuro was…

Ireland Dr. Terry McWade, CEO of Valitacell, discusses the founding of his company, the ground-breaking technology they are producing, and how this technology can help to bring new biologic medications to market faster and more cost-effectively. Having just won the Seedcorn Competition as well as being placed on the list of…